This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEA6606G_M.jpg
“We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer.”
Boustead Securities will serve as lead underwriter.
